Compare AFLAC Incorporated (AFL) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Bristol-Myers Squibb Co — how do they compare? AFLAC Incorporated trades at $120.52 (market cap $60.70B), while Bristol-Myers Squibb Co trades at $63.88 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.1× AFLAC Incorporated's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| AFL | BMY | |
|---|---|---|
Market Cap | $60.70B | $129.94B |
Sector | Financials | Health |
52-Week High | $129.55 | $65.89 |
52-Week Low | $103.55 | $42.60 |
Enterprise Value | $70.65B | $163.92B |
Dividend Yield | 2.02% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
